Immunomedics Initiates Two Pivotal Phase III Trials in Lupus

June 3, 2005

Immunomedics has begun patient dosing for the pivotal Phase III clinical trials to further evaluate the safety and efficacy of the company's lead drug candidate, epratuzumab, for the treatment of patients with systemic lupus erythematosus (SLE), known as lupus.

Epratuzumab has been designated by the FDA as a fast-track product for the potential treatment of patients with moderate and severe SLE. Epratuzumab is a humanized monoclonal antibody that targets an antigen, known as CD22, found on the surface of a certain class of lymphocytes, a type of white blood cell.